Company intelligence / Profile preview
Abyssinia Biologics
Durham or Portsmouth*, New Hampshire, United Statesaby-bio.com ↗
- Ownership
- Private
- Employees
- ~10
- Development stage
- Preclinical
01
Overview
Abyssinia Biologics has developed proprietary monoclonal antibodies that selectively bind toxic soluble amyloid-beta oligomers implicated in early Alzheimer’s pathology. Their lead candidates have demonstrated high selectivity in preclinical studies compared to other anti-Aβ therapies. The company also published data on an ultra-sensitive plasma immunoassay capable of detecting these toxic species as a potential companion diagnostic. All programs remain at the preclinical stage with no reported clinical trial results yet.
- Therapeutic areas
- Neurology
- Modalities
- Monoclonal antibodies (mAbs)Immunoassays/DiagnosticsVaccines (preclinical immunogen)
- Industry
- Biotech
02
Drug pipeline
5 assets4 more assets in the full pipeline.
03
Partnerships
Actively seeking partnerships in CNS space but none publicly announced yet.
Beyond the preview
Go deeper on Abyssinia Biologics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Abyssinia Biologics.